We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI-Assisted Non-DNA Based Test Identifies Viral Infections in Minutes

By LabMedica International staff writers
Posted on 11 Jun 2025

Confirming viral infections typically involves DNA sequencing tests, which take hours and may not be available on-site. More...

Moreover, these tests cannot differentiate between live and inactive virus particles. Now, a new diagnostic method can rapidly detect viable viruses within minutes, offering a faster and more informative alternative.

The innovative tool was created by researchers at Osaka University (Osaka, Japa) by combining nanopore sensing technology with artificial intelligence (AI) to distinguish viral particles based on their electrical conductivity. This approach eliminates the need for DNA-based testing and can determine if a virus is active, a crucial insight for timely treatment. The system works by pushing individual viral particles through a nanopore and measuring their unique electrical conductivity waveforms. These waveforms are influenced by the particle’s size, surface charge, and molecular structure. The AI model then analyzes these signals to accurately identify the virus, even distinguishing between closely related viruses within the same family.

To evaluate its accuracy, researchers tested the system on herpes viruses that infect the eye, pathogens known to cause blindness if untreated. Fluid samples from the eye’s aqueous humor were analyzed using both traditional PCR and the new AI nanopore method. According to findings published in PNAS Nexus, the AI nanopore method achieved a sensitivity of 100% and a specificity of 71.4%. When conditions were optimized, specificity rose to over 90%. This technology shows strong potential for improving viral diagnostics, particularly in time-sensitive or resource-limited settings. By identifying active infections quickly and without the need for genetic sequencing, the method could help clinicians make faster, more informed treatment decisions—not only for ocular infections but possibly for a wide range of viral diseases.


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.